Press Release

Immunizing Against Misinformation and Shortsightedness: AVAC Report Injects a Dose of Reality into the Debate on the State of AIDS Vaccine Research

New York, NY , The AIDS Vaccine Advocacy Coalition (AVAC) today released a new report that provides a comprehensive review of recent developments in AIDS vaccine research. AVAC Report 2008: The Search Must Continue explores the issues that have been raised in the wake of the failure of Merck’s vaccine candidate and provides context for the events and major changes of the last year in HIV prevention research.

In the Report’s opening letter, AVAC Executive Director Mitchell Warren says “Enough is enough,” with regard to the misinformation that has crept into some of the public conversations about AIDS vaccine research. In the report, AVAC argues that continuing to move forward with AIDS vaccine research and testing is imperative and lays out recommendations for the AIDS vaccine and HIV prevention field.

AVAC’s 11th annual Report on AIDS vaccines also looks at the comparative advantages of major players, including the U.S. National Institutes of Health and the International AIDS Vaccine Initiative, and analyzes the current environment for decision-making about future clinical trials. The report is available online at www.avac.org/reports.htm.

The AVAC Report comes at a critical time for HIV prevention research. Over the past 12 months, several trials, including vaccine, microbicide, cervical barrier method and herpes-treatment trials, have yielded disappointing results of no efficacy. Recently, a slew of editorials and media coverage have spotlighted AIDS vaccine research and, in some instances, included calls to end public funding or to reapportion funding away from AIDS vaccine research toward existing HIV treatment or prevention interventions. At the same time, there are ongoing discussions at the NIH about whether to launch another vaccine efficacy trial using a strategy developed by the NIH’s Vaccine Research Center.

“With recent pessimistic headlines and the creation of na�ve and false dichotomies between research and clinical trials or between treatment and prevention or existing interventions and new research, we at AVAC say enough is enough,” said Mitchell Warren, executive director of AVAC. “An AIDS vaccine is possible, and it is essential.”

“It’s been a challenging year for the AIDS vaccine field and for HIV prevention research generally, but the recent spate of statements that seem to revise the history of the past few years of AIDS vaccine research are deeply troubling,” said Warren. “Now more than ever, we must maintain momentum in AIDS vaccine and other HIV prevention research while simultaneously continuing to ramp up provision of existing treatment and prevention options for all those who need them.”

“We were all disappointed with the results from the trials of Merck’s vaccine candidate last year,” said Pontiano Kaleebu, Assistant Director of the Uganda Virus Research Institute, Chairperson of the African AIDS Vaccine Programme, and an AVAC board member. “But we must now reclaim the narrative of what happened with trials of that vaccine and of what they mean for the future of AIDS vaccines and HIV prevention. Here in Uganda and throughout Africa and the world, we still desperately need an AIDS vaccine and we are committed to continuing the search.”

“There have been major changes in the AIDS vaccine field and in biomedical HIV prevention research in the last year. The AVAC Report provides a comprehensive and sensible guide to where the vaccine field stands now and where it needs to go,” said Alan Bernstein, executive director of the Global HIV Vaccine Enterprise.

In The Search Must Continue, AVAC makes several key recommendations for moving the AIDS vaccine and HIV prevention research fields forward, based on a comprehensive review of recent events in the field and future plans of the major players in AIDS vaccine and HIV prevention research as well as conversations with researchers, funders, policy makers and community representatives. These recommendations include:
Ensure that the scientific data from the STEP trial are fully assessed and used to inform the design of improved immunization strategies.
Articulate the human discovery trials agenda and balance vaccine discovery and development.
Structure the vaccine field so that there are career paths for young investigators.
Prepare for results of the Thai prime-boost vaccine efficacy trial.
Systematically improve community engagement strategies, especially as decisions are made around the design of the PAVE 100 vaccine trial.
Clearly communicate and manage expectations of prevention research trials and results.
Increase support for pre-exposure prophylaxis (PrEP) research as well as community stewardship of this promising area of research.
Engage in meaningful dialogue around the scaling-up of male circumcision programs that adequately address HIV testing and gender-specific issues in program rollout.
Expand community engagement with and critique of the microbicides science agenda.
Reconsider how clinical trials infrastructure is sustained and clinical research agendas are developed, in discussion led by developing country voices.

The Report is being released ahead of HIV Vaccine Awareness Day, May 18th, which commemorates U.S. President Bill Clinton’s call for a concerted effort to develop an AIDS vaccine within a decade. Today, it is a global observance to recognize and thank the thousands of volunteers, community members, health professionals, researchers and scientists who are working together to find a safe and effective AIDS vaccine.

“Yes, we have all been surprised and disappointed in the results of the Merck vaccine candidate,” Warren said. “But that is the nature of the scientific process. To acknowledge failure of a candidate vaccine is in no way to concede overall defeat. We all now have a tremendous opportunity to learn from these setbacks and to be better for them, better, even, than we might have been without them. This year, as we commemorate HIV Vaccine Awareness Day, AVAC remains committed and cautiously optimistic.”

# # #

About AVAC: Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options. For more information, visit http://www.avac.org/.

Press Release

Safety of Trial Volunteers Must Remain Paramount Concern

 

WedSeattle, Washington, November 7, 2007, The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement today from Executive Director Mitchell Warren in response to the release of new data from the STEP AIDS vaccine study by Merck & Co., the US National Institute for Allergy and Infectious Diseases (NIAID) and the HIV Vaccine Trials Network (HVTN) at a public forum at the HVTN meeting today.

The data from the STEP study released today confirm that the vaccine was not effective at either preventing infection in male volunteers or at reducing viral loads in male vaccine recipients who became infected with HIV during the trial. In addition, the data suggest that the vaccine may have made some volunteers more susceptible to acquiring HIV infection. The vaccine itself does not cause HIV. This trend was specifically observed among male volunteers who had high titers of antibody to adenovirus, the cold virus that was used, in a disabled form, in the MRK-Ad5 vaccine candidate.

“These data are deeply disappointing and troubling, and raise more questions than answers for the field of AIDS vaccine. Today’s discussion of the data underscores the leadership and transparency that Merck, NIAID, and HVTN continue to show in this complex and challenging time. What is clear is that the field must continue to work on this challenge and on the larger goal of finding a safe and effective AIDS vaccine.

“As much as we would like to see a clear answer in these results to whether or not the vaccine made some volunteers more susceptible to HIV infection, the reality is that there is still significant confusion about the underlying explanation for the observed effect.

“As we move forward, the work of analyzing and interpreting the data from the STEP study, and from the companion Phambili study in South Africa, will become even more difficult and even more important.

“In the weeks and months to come, we look to the AIDS vaccine field as a whole to maintain a collaborative spirit and to commit all necessary resources to the critical work of understanding the potential explanations and implications for the trends observed in the STEP study.

“We commend the trial sponsors for their consistent commitment to the safety of the volunteers, which must be the top priority in this and every other HIV prevention trial. At every stage of this difficult process, trial sponsors and site-level staff must continue to clearly communicate key information about the data and the participants’ potential risk to volunteers at every site.

“AVAC recognizes that these data leave the AIDS vaccine field with a range of difficult decisions.  Going forward, we believe that the wisest course of action is also the most cautious. To safeguard future trials and  volunteers, the trial sponsors and the field as a whole should take as long as is needed to analyze the data and attempt to come to more definitive conclusions about what these new data mean, before beginning efficacy trials of other vaccine candidates.

“In addition, if there is the possibility that unblinding the STEP study and informing every participant about whether he or she received the placebo or the vaccine will provide an additional safeguard for participants, then this is the course of action that should be taken. AVAC believes that ultimately the decision about unblinding the trial should be guided by the participants’ own concerns and priorities.

“Above all, we must continue to see this for what it is: a major setback for the AIDS vaccine field, but one that can and must be overcome through rigorous scientific investigation, open communication with communities, and a firm commitment to the shared goal of reversing the course of the AIDS epidemic in our lifetimes.”

AVAC will continue to provide updates, analysis and resource materials at http://avac.org/pr_step_study.htm as the decision about unbinding the trial is made and as more analyses and data are released. 

# # #

Press Release

AVAC Statement on Phambili and STEP trials: Trial Participant Safety is the Top Priority

New York and Johannesburg — The AIDS Vaccine Advocacy Coalition (AVAC) issued the following statement with regard to recent announcements about the Phambili AIDS vaccine trial in South Africa.

“We are deeply concerned by and share the disappointment of the field regarding the October 23 announcement that the immunizations would be stopped in the Phambili trial of Merck’s Ad5 candidate, and that volunteers in that study would be counseled that receiving the vaccine might have increased their risk of acquiring HIV infection,” said Mitchell Warren, AVAC executive director.

“This is a serious setback and heavy blow to the dedicated volunteers, principal investigators, and site staff who have committed their time, energy and optimismto this study. As always, we believe that participant safety is paramount and that where ever doubts arise, monitoring boards and trial sponsors must err on the side of caution.

“At this time, it is not clear whether or not there is definitive evidence that the vaccine did increase participant’s susceptibility. In the absence of this information, we must make sure that all participants in all of the trials of the Merck product understand the basis for the counseling messages about the possibility of increased susceptibility to HIV infection. We must also be cautious about leaping to definitive conclusions until the full data sets have been analyzed.”

On Tuesday, October 23, the South African AIDS Vaccine Initiative (SAAVI) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) issued press statements stating that the Data and Safety Monitoring Board (DSMB) for the Phambili trial [HVTN 503] had reviewed the available data from the STEP study of the same candidate, which halted immunizations in September, 2007.

As the NIAID press release stated, the DSMB made several recommendations: “The DSMB also recommended that HVTN 503 volunteers be told whether they received the vaccine or placebo, be strongly encouraged to return to their study sites for protocol-related tests, and be counseled about the possibility that those who received the vaccine may have an increased susceptibility to acquiring HIV infections.”

“It is very important that the field put forward clear common messages,” said Pontiano Kaleebu, AVAC board member, and principal investigator on AIDS vaccine trials at the Uganda Virus Research Institute. “The search for an AIDS vaccine must continue even when there is bad news. To move forward, all of us — communities, investigators, sites, the media — must work together to convey accurate messages based on the information available.”

Additional data set from the STEP study will be released in a public discussion on November 7, 2007, at HIV Vaccine Trial Network meeting in Seattle, Washington. This meeting will include data on rates and timing of infection from the second 1500 volunteers enrolled in the STEP study.

“It is hoped that exploration of this additional data from STEP will add to our understanding of what happened in that trial, and shed additional light on many questions, including whether vaccine recipients did indeed have increased risk of acquiring HIV,” said Warren.

# # #

About AVAC
Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options. To help assure its independence, AVAC does notaccept funding from government or pharmaceutical industry sources. For more information, visit http://www.avac.org.

Press Release

AIDS Vaccine Advocacy Coalition Voices Disappointment in Trial Result – Applauds Merck’s Leadership and Calls for Reinvigorated Effort to Design and Test AIDS Vaccines

New York, September 21, 2007 — The AIDS Vaccine Advocacy Coalition (AVAC) released the following statement from Executive Director Mitchell Warren about the announcement that vaccinations have been discontinued in the STEP Study, a test-of-concept trial of the MRK-Ad5 AIDS vaccine candidate developed by the Merck Research Laboratories:

“Today’s announcement about the STEP Study is a deep disappointment and a scientific setback for the AIDS vaccine field. However, it must be seen for what it is: the failure of a product to show efficacy in a specific trial. Clinical testing of AIDS vaccines is a scientific process and, while this is a disappointment, it is in no way the end of the search for an AIDS vaccine.

“These data are certainly not the ones that we had hoped for. The entire HIV vaccine field, including AVAC, had been looking to STEP and its companion Phambili trial in South Africa, to provide initial evidence of vaccine-related benefits. Even as the data disappoint, we also note the success of the STEP Study trial design in providing a swift answer to the critical question of whether or not the vaccine provided any benefits. A successful clinical trial is one that produces a scientifically accurate result. It may not be the result you had hoped for, but it answers questions that help the field move forward.

“We applaud Merck’s tremendous leadership on HIV vaccine research. The company has set an example for the field, taking on one of the most important health technology challenges of our time. Merck and its collaborator, the US NIH-funded HIV Vaccine Trials Network, have been committed, strategic and willing to take risks at every stage of evaluating MRK-Ad5, and they must be commended for this. AVAC also recognizes the contributions of the thousands of volunteers in these trials. Their altruistic involvement makes HIV vaccine research possible. It is essential to build on what has been learned here and proceed with further research as rapidly as possible. Millions of lives are at stake.

“In the next weeks and months the AIDS vaccine field will need to make carefully-considered decisions about whether to move forward with planned trials of related vaccine strategies, and how to proceed with the Phambili trial, which has paused immunizations and enrollment. AVAC is committed to working with many other stakeholders in the AIDS vaccine field and in other areas of AIDS prevention research to ensure that these discussions are thoughtful, transparent, and clearly communicated to global audiences.

“These results do not change our fundamental view. Developing an AIDS vaccine will require a series of large-scale human trials in many different countries over a number of years. These trials need to be designed to produce clear results and to design better candidates in the future. This research must be complemented by ongoing studies of other new biomedical prevention strategies, and by full-scale, fully-funded implementation of proven prevention and treatment strategies.”

About the STEP Study
An interim analysis of data from the study, involving over 3,000 people testing an adenovirus-based vaccine (MRK-Ad5) developed by the Merck Research Laboratories, showed no efficacy in protecting against new infections or in reducing viral load in people who received the vaccine and went on to become infected. The study was scheduled to end in 2009. Periodic reviews of data by an independent monitoring board are part of the clinical trials process, and the study was halted on the recommendation of the STEP Study monitoring board after a regularly-scheduled review.

There have been two previous efficacy trials of an AIDS vaccine candidate, called AIDSVAX. Both of these studies took more than five years from launch to announcement of the finding, that the candidate did not protect against infection. The STEP Study enrolled its first participant in December 2004, and we have a definitive answer less than three years later. Getting swift, precise answers about candidates is crucial for the field. In this sense, the STEP Study fulfilled its purpose, as disappointing as the results may be.

One reason for this efficiency is that both STEP and its companion trial Phambili, which tested the candidate in South Africa, were designed as “test-of-concept” trials, to give an initial answer about vaccine benefits in a relatively abbreviated timeframe. The STEP Study met its enrollment targets and its endpoint goals within the timeframe specified by the trial planners. 

# # #

Press Release

AIDS Vaccine Advocacy Coalition Receives $14 Million Grant from Gates Foundation to Develop International HIV Prevention Research Advocacy Network

New AVAC Report on the State of the AIDS Vaccine Field Calls for Accelerated Action in AIDS Vaccine and HIV Prevention Research

Seattle — The AIDS Vaccine Advocacy Coalition (AVAC) announced today at the AIDS Vaccine 2007 Conference that it has received a five-year, $14 million grant from the Bill & Melinda Gates Foundation to create a new international HIV Prevention Research Advocacy Network.  The Advocacy Network will work with civil society, policymakers, and research partners around the world to advance ethical research and development of new HIV prevention interventions, ensure that communities are informed about and involved in prevention research, and ensure that the benefits of research are shared globally.

The new grant broadens AVAC’s advocacy focus beyond AIDS vaccines, to include other new HIV prevention interventions such as microbicides and oral prevention drugs.

“We are entering a new era in HIV prevention research, with more products being tested in efficacy trials than ever before,” said Mitchell Warren, Executive Director of AVAC.  “A coordinated global effort is urgently needed to support the wide range of prevention research, to ensure that the voices of civil society and communities are heard, and to prepare for results from these trials.”

“It is essential to build support for and understanding of how new HIV prevention tools will help accelerate efforts to slow this epidemic,” said Joe Cerrell, Director of Global Health Advocacy for the Gates Foundation.  “AVAC has been an important voice in AIDS vaccine advocacy for the last decade, and we are extremely pleased to support this broadening of its work.”

“This generous grant from the Gates Foundation will allow AVAC to expand our advocacy efforts and build a global network of advocates who will work to promote HIV prevention research and help communities prepare for the use of new HIV prevention options,” said Mike Powell, President of the AVAC Board of Directors.

AVAC remains committed to advocacy for effective AIDS vaccines, and will now be able to expand its work.  The new international HIV Prevention Research Advocacy Network will:
� Develop international advocacy partnerships that support both the needs of communities involved in research and a global advocacy movement for HIV prevention research.
� Translate complex scientific ideas to communities AND translate community needs and perceptions to the scientific community.
� Work to hold both research agencies and advocates accountable for accelerating ethical prevention research and development.
� Help ensure that communities, policymakers, and civil society have realistic expectations about HIV prevention research and specific clinical trials.
� Work closely with other groups conducting HIV prevention research advocacy, including microbicide advocacy groups.

“With so many clinical trials of HIV prevention interventions underway or planned in the next few years, there is an urgent need for a global advocacy network that will expand and support partnerships among the different groups working in the field,” said Lori Heise, Director of the Global Campaign for Microbicides.

Developing and maintaining strong support for clinical research of new HIV prevention interventions can be difficult in many communities and countries, but is necessary if ethical research is to take place in these communities.  The Advocacy Network will link advocates, researchers, and policymakers from around the world and will share information and identify and promote “good practices” for advocacy and clinical research.

“This network will provide an important knowledge base for those of us working on and supporting clinical trials in our communities,” said Manju Chatani, coordinator of the African Microbicides Advocacy Group. “We look forward to working with AVAC and other partners to strengthen HIV prevention research advocacy here in Africa and in communities around the world.”
Resetting the Clock — New AVAC Report Examines State of the AIDS Vaccine Field and Calls for New, Ambitious Deadlines for Vaccine Development

AVAC also released its annual report examining the state of the AIDS vaccine field today at the AIDS Vaccine 2007 Conference.  The new report, entitled Resetting the Clock, outlines the specific deadlines and challenges facing the field in the arenas of AIDS vaccine scientific strategy, clinical trials, and the broader prevention field and provides recommendations for action by researchers, policymakers, industry, funders, civil society, and advocates, including AVAC.

The report also discusses progress and challenges of the Global HIV Vaccine Enterprise, an alliance of independent partners committed to accelerating the development of an AIDS vaccine. AVAC is one of the founding stakeholders of the Enterprise.

“We will soon have data from the test-of-concept studies of novel AIDS vaccine candidates,” said Warren.  “It is time to reset the clock to launch a countdown for meeting new, ambitious deadlines for developing new vaccine concepts and candidates that will be needed whether or not there is evidence of benefit from these first test-of-concept trials.”

Key features of Resetting the Clock include:
� New Countdowns looks at progress and barriers in funding and strategy-setting for the vaccine field, addresses key questions about what needs to be done as we wait for the results from current trials, and looks at the responsibilities of key institutions.  It also includes an updated industry survey.
� Racing Against Time examines clinical trials issues and finds that the field is already in danger of slipping behind on several fronts, including clinical trials capacity, consensus on standards of prevention and levels of care, and new funding structures for US prevention research networks.
� Wake Up Call explores the critical lessons to be learned from responses to male circumcision and HPV vaccine introduction.  It also includes a survey of advocates from other areas of the AIDS response about prevention research.
“This report shows that the current state of HIV prevention research is troubling and challenging.  It is time for all AIDS advocates to re-exam�ine their messages, their missions, and their goals for the next five to ten years,” said Warren.  “We at AVAC remain committed to our advocacy for an effective AIDS vaccine and are excited about expanding the scope of our work to include the broader field of HIV prevention research and working with new partners around the globe to ensure that the world finds a way to defeat HIV/AIDS.”

Resetting the Clock is available online at http://www.avac.org/reports.htm.

# #

About AVAC
Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options. For more information, visit http://www.avac.org.

Press Release

AIDS Vaccine Advocacy Coalition calls for renewed commitment to vaccine research on anniversary of President Clinton’s 10-year challenge

Call for new urgency, targets and leadership to accelerate research on HIV Vaccine Awareness Day

New York, NY — On May 18, 1997, US President Bill Clinton called for a concerted effort to develop an AIDS vaccine within a decade. This year we mark the 10th anniversary of that call for action with a global AIDS epidemic that rages on, and without a preventive HIV vaccine.

“Over the past decade, we have seen great progress in AIDS vaccine development, and we now see signs of great hope for development of a vaccine,” said Mitchell Warren, Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC). “But we have fallen short of the goal set out by President Clinton. Critical elements of the accelerated, comprehensive effort that we need to deliver on the promise of an AIDS vaccine are missing.”

In its special HIV Vaccine Awareness Day report, “The Countdown Continues” (available at http://avac.org/pdf/hvad_the_countdown_continues.pdf), AVAC identifies key issues and obstacles to an accelerated, comprehensive approach to AIDS vaccine development and challenges vaccine researchers, advocates, and funders to:

�    Accelerate and better coordinate research and testing of vaccines and other potential new HIV prevention technologies.
�    Sustain clinical trial capacity internationally, especially in communities where the HIV epidemic is most severe.
�    Develop bold and well-resourced plans for vaccine research and community education in all populations at high risk for HIV infection, not only those who are “easier” to reach.
�    Prepare for results of current AIDS vaccine efficacy trials by examining different efficacy scenarios.
�    Ensure that research results of all current trials are widely shared in order to help develop better next generation AIDS vaccine candidates.
�    Urgently expand access to proven HIV prevention options and treatment for all who need them.
�    Bring new, young investigators into AIDS vaccine research.

Ten years ago, President Clinton said, “[W]ith the strides of recent years, it is no longer a question of whether we can develop an AIDS vaccine, it is simply a question of when.”  While the dream of having that vaccine in the first decade of the 21st century has not come true, the world has, nonetheless, made tremendous advances in the past decade.
Global resources for AIDS vaccine development, while still short of what is needed, have quadrupled; the number of countries with clinical trials capacity has expanded from North and South America and Europe to include Asia and Africa; and more than 25,000 brave men, women, and children have stepped forward to volunteer for AIDS vaccine trials around the world.

On this anniversary, AVAC reaffirms its commitment to advocacy for a new clinical trials paradigm that recognizes the need for partnerships that include those from scientific and non-scientific domains. These partnerships both improve research and ensure that communities can immediately benefit from the conduct of clinical trials whose ultimate goal , an AIDS vaccine , may still be years away.

“If we are to sustain the necessary momentum to develop and distribute an AIDS vaccine, advocates, activists, scientists, trial volunteers and concerned citizens must work together to create a new paradigm for AIDS vaccine research and development. We must get better at answering the �question of when,’ and be able to explain why it is taking so long to develop a vaccine. And we must also take every step necessary to ensure that delays are avoided, whether in product development, regulatory decisions, or manufacturing,” said Warren.
“If one candidate fails, we must ensure that communities everywhere know this is not the end of the road. We must be sure that there is another candidate moving steadily forward into clinical trials,” he added. “We will ultimately measure the search for an AIDS vaccine in decades, but both President Clinton’s sense of urgency and optimism must remain with us as we continue the countdown to a day when the AIDS epidemic is over.”

# # #

About AVAC:
Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options. For more information, visit www.avac.org.

About HIV Vaccine Awareness Day:
Each year on May 18th, people around the world commemorate HIV Vaccine Awareness Day, an observance to recognize and thank the thousands of volunteers, community members, health professionals, researchers and scientists who are working together to find a safe and effective HIV vaccine. It is also a day to educate our communities about the importance of HIV vaccine research and development. More information at http://avac.org/hvad.htm.

Press Release

AIDS Vaccine Advocacy Coalition Calls for Strategic Leadership and Urgency in the Implementation of Male Circumcision for HIV Prevention

New York, NY — Mitchell Warren, Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC) today issued the following statement regarding the new recommendations from the World Health Organization (WHO) and UNAIDS on male circumcision as an HIV prevention strategy.  

“AVAC welcomes the new recommendations from WHO and UNAIDS on the range of policy, operational and ethical issues that will help guide countries about where and how male circumcision can be best implemented, promoted, and safely performed. These normative recommendations are essential to ensuring successful rollout of male circumcision to protect against HIV infection.

“Adding the offer of safe, sterile, voluntary male circumcision to existing HIV prevention programs could avert many infections and save many lives. These programs could also provide a new way to reach men and adolescent boys who are frequently under-represented in health clinics and HIV prevention programs.
 
“As important as the new recommendations are, though, they are only a first step in translating research findings into real public health impact. This international guidance document must now be complemented by funding, technical assistance and operational research at the country level to help national governments and health ministries develop and implement policies and programs to ensure that male circumcision is as part of a comprehensive package of prevention interventions.

“If these resources are not immediately forthcoming, there is a real risk that the benefits of male circumcision will be negated by complications relating to unsafe surgeries performed by unskilled practitioners seeking to profit from demand, which is likely to increase as news of these data spread through communities around the world.

“It is also absolutely critical to recognize the unanswered questions about male circumcision, including: whether it is safe for HIV-positive men and their partners; whether it provides any protective benefit to women who are sexual partners of circumcised, HIV-positive men; and whether it has any protective benefit in the context of anal sex.

“But not having all the answers should not stop us from making the first big steps of using the overall finding to help reduce new infections. Making and resourcing clear plans for filling in these gaps must be given equal priority to rollout based on what we know today.

“The benefits of male circumcision can only be realized if male circumcision is offered in programs that contain clear, cultural and context-specific messages and that explain the benefits and limitations of the procedure for men and their sexual partners and the importance of proper wound healing before resuming sexual activity.

“Policymakers will face complex decisions as they seek to implement these recommendations. Decisions about targeting high-risk men should be made with the utmost care, and it is also essential that circumcision not become falsely viewed as an indicator of HIV-negative serostatus. Programs must develop communications strategies and packages of services that counter this impression and meet the needs of HIV-negative men, HIV-positive men, and especially their partners.

“Research and dialogue are also needed now to explore the feasibility of rolling out infant circumcision. This approach will not show immediate benefits in terms of HIV incidence but can minimize risks and could be a highly cost-effective implementation strategy over the long term.”

AVAC’s report on understanding the results of the male circumcision trials as well as a detailed statement on research priorities for male circumcision and advocacy fact sheets for civil society in the US and in sub-Saharan Africa are available at www.aidsvaccineclearinghouse.org/MC.

About AVAC: Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other prevention options.

Press Release

AVAC Applauds Commencement of First HIV Vaccine Efficacy Trial in Africa

New York, New York — The AIDS Vaccine Advocacy Coalition (AVAC) heralds today’s launchof the first African efficacy trial of an experimental HIV vaccine as a critical, strategic and historically-significant step in the search for an AIDS vaccine.

The trial, which is known as Phambili (a Xhosa word meaning “moving forward”) or HVTN 503, was launched today in South Africa by the South African AIDS Vaccine Initiative (SAAVI) and the HIV Vaccine Trials Network (HVTN) of the US National Institutes of Health.

“South Africa and the partner agencies in this study are demonstrating tremendous leadership. With the stakes as high as they are in the epidemic, accelerating large-scale efficacy trials in the countries and communities that need an HIV vaccine the most is the kind of forward-looking, strategic decision-making that the field needs and should embrace,” said Mitchell Warren, Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC).

The same vaccine candidate, which has been developed by Merck Research Laboratories, is currently being tested in another efficacy trial being conducted in various sites in North and South America, the Caribbean and Australia. The data from this study, known as the Step Study, are not yet known. Phambili has been initiated before the conclusion of the Step Study to help speed the progress of gathering additional important data in sub-Saharan Africa.

“The timing of the Phambili trial launch is a bold decision,” said Warren. “There is an urgent need to identify new AIDS prevention strategies as quickly as possible; this sequence of trials will help move the field forward as quickly as possible. These two trials will combine to shed light on whether this vaccine candidate has the potential to be a truly global vaccine that can eventually be used in both developed and developing countries.”

“As this trial moves forward, AVAC also hopes that this vaccine candidate will also be studied among adolescents. Adolescents are at great risk of HIV infection, and AVAC strongly supports the inclusion of adolescents in future trials so that we can get answers as quickly as possible for this priority population,” Warren said.

“Finding an effective AIDS vaccine will not happen in one isolated sector or country, but from international collaborations between industry, government agencies, academia, and publicprivate partnerships. Phambili is an excellent example of putting public funds to good use to test a promising vaccine candidate,” Warren said.

While there have been a significant number of small and mid-size safety studies conducted in sub-Saharan Africa, Phambili is the first study that is designed to provide information on whether or not a vaccine protects against HIV infection or helps to blunt HIV disease. Neither the Step study nor the Phambili trial has been designed as the final study of this vaccine candidate; if there are indications of efficacy, additional studies will be conducted to confirm this preliminary finding.

About AVAC: Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a nonprofit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other prevention options. For more information, visit www.avac.org.

Press Release

Leading advocates express support for microbicide research, despite disappointing clinical trial results

HIV prevention advocates from three major civil society organizations today emphasized the importance of continued research into new HIV prevention options, despite the recent discontinuation of the Phase III effectiveness trials of the microbicide candidate, cellulose sulfate (CS).

CS was one of the four microbicide candidates in Phase III effectiveness trials for prevention of HIV and other sexually transmitted infections. CONRAD, a reproductive health research organization, was conducting Phase III trials to assess its effectiveness in Benin, India, South Africa, and Uganda. Another Phase III trial of CS sponsored by Family Health International was underway in Nigeria. Both sponsors are not-for profit research groups dedicated to advancing health in developing countries.

At the recommendation of their respective Data Safety Monitoring Boards both sponsors chose to discontinue their CS trials after findings from the CONRAD trial suggested that CS might be contributing to an increased risk of HIV infection. Although review of the data from the Nigerian trial found no evidence of increased risk, FHI felt that the only responsible course of action was to halt its study also.

“Of course we wish the results had been different, but learning what doesn’t work can be just as important to progress as learning what does work,” observed Lori Heise, Director of the Global Campaign for Microbicides (GCM). “It’s also reassuring that the independent Data Safety and Monitoring Committees, put in place to identify problems early on in a trial, appear to have worked well. Advocates have been instrumental in pushing for extra mechanisms to help protect participant safety.”

African advocates are following the trials conducted in their countries particularly closely, reported Manju Chatani, Coordinator of the African Microbicide Advocacy Group (AMAG).  “Scientists scrutinized the data available on cellulose sulfate before the Phase III trials started, including safety results from 11 clinical trials done in Africa, India and the US. All the data suggested that the product was safe and should proceed into Phase III trials,” she said.

“This is a setback but it does not detract from the issue that women still don’t have the tools they need to protect themselves from HIV”, Chatani added. “And African women, especially, urgently need more prevention options. So while we need concrete answers to why this happened as soon as possible, we must continue to research new options so women don’t have to ask for permission to protect themselves”

Dr. Kim Dickson, an African physician who serves on the boards of both GCM and AMAG, noted that care and treatment of trial participants are among the top concerns of both groups, along with clinical trial ethics. “At civil society’s insistence, the trial investigators forged written agreements in advance to assure that any women who sero-converted while enrolled in the trial would get ongoing care and treatment, including anti-retroviral drugs as needed”, she said. “Our priority now is to make sure that advocates’ and community questions about this trial and future research are heard and addressed as soon as possible.”

Adding his perspective, Director of the AIDS Vaccine Advocacy Coalition (AVAC) Mitchell Warren observed that “Getting a negative result for one product certainly doesn’t signal failure for the microbicide field or broader biomedical HIV prevention research effort as a whole. The nature of research is that the information gathered is cumulative”, he continued. “Each trial result is a puzzle piece and, together, they make up the complex picture that will show us how to develop successful new HIV prevention tools.”

Heise concluded by noting that “The real heroines and heroes in this are the people who enroll in clinical trials because they know how urgently new prevention tools are needed. In Benin, South Africa, and Uganda, the African countries in which the CS trials were being done, between one third and one half of all women of reproductive age are already HIV positive”, she added. “It is essential to build on what has been learned here and proceed with the research as rapidly as possible. Millions of women’s lives are at stake.”

# # #

The Global Campaign for Microbicides is an international movement of activists, citizens and not for profit organizations dedicated to accelerating access to new HIV prevention tools, especially for women. www.global-campaign.org. Dr. Kim Dickson. +41 (22) 791 4548; cell: + 41 79 368 6259.

The African Microbicides Advocacy Group (AMAG) is a coalition of microbicide advocates from organisations and institutions based and/or working in various African countries. www.globalcampaign.org/amag.htm. Contact: [email protected]; + 233 21 225 180; cell: +233-244-503026

The AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options.
www.avac.org.
Contact: [email protected], +1 212 367 1084.

Contact for Family Health International: Beth Robinson, + 1 919 405 1461, [email protected],
http://www.fhi.org/en/AboutFHI/Media/index.htm

Contact for CONRAD: Annette Larkin, +1 202 429 4929, cell: +1 703 772 6427,
[email protected]

Press Release

HIV Vaccines and Microbicides Resource Tracking Working Group Releases Preliminary Data and Launches New Website

The HIV Vaccines and Microbicides Resource Tracking Working Group was established in 2004 to generate and disseminate high-quality, detailed and comparable data on annual investments in preventive HIV vaccine and microbicide research and development (R&D), and policy and advocacy activities. These data can be used to monitor current levels of effort; identify trends in investment, spending, and research focus; identify areas needing more resources and effort; assess the impact of public policies aimed at increasing investment in new prevention technologies (NPTs); and provide a fact base for policy advocacy on R&D investments and allocations.

The Working Group is comprised of the AIDS Vaccine Advocacy Coalition (AVAC), the Alliance for Microbicide Development (AMD), the International AIDS Vaccine Initiative (IAVI) and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

To coincide with the current UNGASS review taking place this month, the Working Group has generated new estimates of public sector investment in HIV vaccine and microbicide research, development, and advocacy in 2005.

According to a preliminary report, the public sector invested an estimated US $654 million in preventive HIV vaccines and about US$ 139 million in microbicides in 2005. A full report on global investment in these technologies – including funding from philanthropic institutions and private industry – will be available in August 2006.

We have launched a new website at http://www.hivresourcetracking.org/ has this latest report as well as the reports published on each technology in 2005 along with PowerPoint slide presentations with the report results.

For more information on HIV vaccines, please contact the AIDS Vaccine Advocacy Coalition ([email protected]) or the International AIDS Vaccine Initiative([email protected]).

For more information on microbicides, please contact the Alliance for Microbicide Development ([email protected]).

For more information on UNAIDS resource tracking activities, please contact the UNAIDS Resource Tracking Unit ([email protected]).